Zimmer Biomet’s Q3 2025 Earnings: What to Expect

Core Viewpoint - Zimmer Biomet Holdings, Inc. is facing challenges with sales growth and operational expenses, leading to a cautious outlook despite expected earnings growth in the upcoming quarters [5][6]. Financial Performance - The company is expected to report an adjusted EPS of $2.38 for fiscal Q4 2025, reflecting a 3% increase from $2.31 in the same quarter last year [2]. - For fiscal 2025, analysts predict an adjusted EPS of $8.16, a 2% rise from $8 in fiscal 2024, with further growth projected to $8.41 in fiscal 2026, representing a 3.1% year-over-year improvement [3]. Stock Performance - Zimmer Biomet's shares have declined by 12.5% over the past 52 weeks, underperforming the S&P 500 Index, which increased by 19.7%, and the Health Care Select Sector SPDR Fund, which rose by 12.7% during the same period [4]. - The stock's underperformance is attributed to disappointing sales growth, lowered guidance, competitive pressures, and operational challenges [5]. Analyst Sentiment - The consensus rating for Zimmer Biomet stock is a "Hold," with 26 analysts covering the stock: six recommend a "Strong Buy," one a "Moderate Buy," 16 a "Hold," and three a "Strong Sell" [6]. - The average analyst price target for Zimmer Biomet is $102.73, indicating a potential upside of 12.3% from current levels [6].